SHERITA WILLIS: Open Payments
NPI 1740326610 · OSCEOLA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$275 in 9 payments from 7 companies in 2025. Trend: 2023 $270 · 2024 $313 · 2025 $275
Food & beverage: $275
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 1 | $94 |
| ABBVIE INC. | 3 | $71 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Novo Nordisk Inc | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: LINZESS, GEMTESA, Ozempic, COBENFY, VIBERZI, XIFAXAN, CAPLYTA.
Industry payments across AR — which companies pay providers there.
